The DOI matches its Crossref record; 302 of the 302 references it cites were found in a registry or an index.
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
Open accessAbstract
Cancer nanotherapeutics are progressing at a steady rate; research and development in the field has experienced an exponential growth since early 2000’s. The path to the commercialization of oncology drugs is long and carries significant risk; however, there is considerable excitement that nanoparticle technologies may contribute to the success of cancer drug development. The pace at which pharmaceutical companies have formed partnerships to use proprietary nanoparticle technologies has considerably accelerated. It is now recognized that by enhancing the efficacy and/or tolerability of new drug candidates, nanotechnology can meaningfully contribute to create differentiated products and improve clinical outcome. This review describes the lessons learned since the commercialization of the first-generation nanomedicines including DOXIL® and Abraxane®. It explores our current understanding of targeted and non-targeted nanoparticles that are under various stages of development, including BIND-014 and MM-398. It highlights the opportunities and challenges faced by nanomedicines in contemporary oncology, where personalized medicine is increasingly the mainstay of cancer therapy. We revisit the fundamental concepts of enhanced permeability and retention effect (EPR) and explore the mechanisms proposed to enhance preferential “retention” in the tumor, whether using active targeting of nanoparticles, binding of drugs to their tumoral targets or the presence of tumor associated macrophages. The overall objective of this review is to enhance our understanding in the design and development of therapeutic nanoparticles for treatment of cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Self-citationMatsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
In vivo cancer targeting and imaging with semiconductor quantum dots
Gao, X., Cui, Y., Levenson, R. M., Chung, L. W. K., & Nie, S. (2004) · Nature Biotechnology · doi:10.1038/nbt994 · Cited by 4,772
Mammen, M., Choi, S.-K., & Whitesides, G. M. (1998) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19981102)37:20<2754::aid-anie2754>3.0.co;2-3 · Cited by 4,110
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699 · cited 1×
“Therefore, the approach is aimed towards increasing interactions between NPs and cell and enhancing internalization of drugs without altering the overall biodistribution [6, 145, 146].”
BackgroundSelf-citationStrategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Impact of Nanotechnology on Drug Delivery
Farokhzad, O. C., & Langer, R. (2009) · ACS Nano · doi:10.1021/nn900002m · Cited by 3,348
Self-citation
Cited by
Items 101–167 of 167
Nanomaterials for T-cell cancer immunotherapy
Gong, N., Sheppard, N. C., Billingsley, M. M., June, C. H., & Mitchell, M. J. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00822-y · Cited by 306
Ultrasmall inorganic nanoparticles: State-of-the-art and perspectives for biomedical applications
Zarschler, K., Rocks, L., Licciardello, N., Boselli, L., Polo, E., Garcia, K. P., De Cola, L., Stephan, H., & Dawson, K. A. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2016.02.019 · Cited by 303
Sonodynamic therapy (SDT): a novel strategy for cancer nanotheranostics
Pan, X., Wang, H., Wang, S., Sun, X., Wang, L., Wang, W., Shen, H., & Liu, H. (2018) · Science China Life Sciences · doi:10.1007/s11427-017-9262-x · Cited by 302
Two-Dimensional Graphene Augments Nanosonosensitized Sonocatalytic Tumor Eradication
Dai, C., Zhang, S., Liu, Z., Wu, R., & Chen, Y. (2017) · ACS Nano · doi:10.1021/acsnano.7b05215 · Cited by 301
Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far?
Hegde, M., Girisa, S., BharathwajChetty, B., Vishwa, R., & Kunnumakkara, A. B. (2023) · ACS Omega · doi:10.1021/acsomega.2c07326 · Cited by 301
Gao, S., Li, T., Guo, Y., Sun, C., Xianyu, B., & Xu, H. (2020) · Advanced Materials · doi:10.1002/adma.201907568 · Cited by 300
Recent Developments of Liposomes as Nanocarriers for Theranostic Applications
Xing, H., Hwang, K., & Lu, Y. (2016) · Theranostics · doi:10.7150/thno.15464 · Cited by 296
Wang, X.-G., Dong, Z.-Y., Cheng, H., Wan, S.-S., Chen, W.-H., Zou, M.-Z., Huo, J.-W., Deng, H.-X., & Zhang, X.-Z. (2015) · Nanoscale · doi:10.1039/c5nr04045k · Cited by 291
Ruan, S., Cao, X., Cun, X., Hu, G., Zhou, Y., Zhang, Y., Lu, L., He, Q., & Gao, H. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.05.006 · Cited by 290
Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment
Xu, X., Liu, C., Wang, Y., Koivisto, O., Zhou, J., Shu, Y., & Zhang, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113891 · Cited by 289
Self-citationNano-palladium is a cellular catalyst for in vivo chemistry
Miller, M. A., Askevold, B., Mikula, H., Kohler, R. H., Pirovich, D., & Weissleder, R. (2017) · Nature Communications · doi:10.1038/ncomms15906 · Cited by 288
The Emerging Role of Multifunctional Theranostic Materials in Cancer Nanomedicine
Figueiredo, P., Bauleth-Ramos, T., Hirvonen, J., Sarmento, B., & Santos, H. A. (2018) · Handbook of Nanomaterials for Cancer Theranostics · doi:10.1016/b978-0-12-813339-2.00001-3 · Cited by 287
Nanoparticle–blood interactions: the implications on solid tumour targeting
Lazarovits, J., Chen, Y. Y., Sykes, E. A., & Chan, W. C. W. (2015) · Chemical Communications · doi:10.1039/c4cc07644c · Cited by 285
Photodynamic therapy: Innovative approaches for antibacterial and anticancer treatments
Kolarikova, M., Hosikova, B., Dilenko, H., Barton‐Tomankova, K., Valkova, L., Bajgar, R., Malina, L., & Kolarova, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21935 · Cited by 282
Design considerations for nanotherapeutics in oncology
Stylianopoulos, T., & Jain, R. K. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.07.015 · Cited by 280
Cooley, M., Sarode, A., Hoore, M., Fedosov, D. A., Mitragotri, S., & Sen Gupta, A. (2018) · Nanoscale · doi:10.1039/c8nr04042g · Cited by 279
Cancer Cell Membrane-Coated Nanoparticles for Cancer Management
Harris, J. C., Scully, M. A., & Day, E. S. (2019) · Cancers · doi:10.3390/cancers11121836 · Cited by 278
Recent Advances in Targeted Drug Delivery Strategy for Enhancing Oncotherapy
Li, J., Wang, Q., Xia, G., Adilijiang, N., Li, Y., Hou, Z., Fan, Z., & Li, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092233 · Cited by 278
Current Applications of Nanoemulsions in Cancer Therapeutics
Sánchez-López, E., Guerra, M., Dias-Ferreira, J., Lopez-Machado, A., Ettcheto, M., Cano, A., Espina, M., Camins, A., Garcia, M. L., & Souto, E. B. (2019) · Nanomaterials · doi:10.3390/nano9060821 · Cited by 276
Pearce, A. K., & O’Reilly, R. K. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00456 · Cited by 275
Nanomicelles: types, properties and applications in drug delivery
Bose, A., Roy Burman, D., Sikdar, B., & Patra, P. (2021) · IET Nanobiotechnology · doi:10.1049/nbt2.12018 · Cited by 278
Engineering and physical sciences in oncology: challenges and opportunities
Mitchell, M. J., Jain, R. K., & Langer, R. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.83 · Cited by 273
ROS-induced NO generation for gas therapy and sensitizing photodynamic therapy of tumor
Wan, S.-S., Zeng, J.-Y., Cheng, H., & Zhang, X.-Z. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.004 · Cited by 272
Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery
Baeza, A., Colilla, M., & Vallet-Regí, M. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.953051 · Cited by 270
Hyaluronic acid and albumin based nanoparticles for drug delivery
Lei, C., Liu, X.-R., Chen, Q.-B., Li, Y., Zhou, J.-L., Zhou, L.-Y., & Zou, T. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.033 · Cited by 266
The protein corona and its effects on nanoparticle-based drug delivery systems
Li, H., Wang, Y., Tang, Q., Yin, D., Tang, C., He, E., Zou, L., & Peng, Q. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.019 · Cited by 265
Design of Nanoparticle-Based Carriers for Targeted Drug Delivery
Yu, X., Trase, I., Ren, M., Duval, K., Guo, X., & Chen, Z. (2016) · Journal of Nanomaterials · doi:10.1155/2016/1087250 · Cited by 265
Glutathione-Responsive Prodrug Nanoparticles for Effective Drug Delivery and Cancer Therapy
Ling, X., Tu, J., Wang, J., Shajii, A., Kong, N., Feng, C., Zhang, Y., Yu, M., Xie, T., Bharwani, Z., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b06400 · Cited by 263
Self-citationRecent advances in targeted antibacterial therapy basing on nanomaterials
Geng, Z., Cao, Z., & Liu, J. (2023) · Exploration · doi:10.1002/exp.20210117 · Cited by 262
Li, S.-Y., Cheng, H., Qiu, W.-X., Zhang, L., Wan, S.-S., Zeng, J.-Y., & Zhang, X.-Z. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.07.026 · Cited by 260
From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases
Pilkington, E. H., Suys, E. J. A., Trevaskis, N. L., Wheatley, A. K., Zukancic, D., Algarni, A., Al-Wassiti, H., Davis, T. P., Pouton, C. W., Kent, S. J., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.023 · Cited by 260
Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery
Waheed, S., Li, Z., Zhang, F., Chiarini, A., Armato, U., & Wu, J. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01605-4 · Cited by 259
Self-citationMetallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
Dogra, P., Adolphi, N. L., Wang, Z., Lin, Y.-S., Butler, K. S., Durfee, P. N., Croissant, J. G., Noureddine, A., Coker, E. N., Bearer, E. L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06730-z · Cited by 257
Xiao, W., & Gao, H. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.10.011 · Cited by 256
Durfee, P. N., Lin, Y.-S., Dunphy, D. R., Muñiz, A. J., Butler, K. S., Humphrey, K. R., Lokke, A. J., Agola, J. O., Chou, S. S., Chen, I.-M., et al. (2016) · ACS Nano · doi:10.1021/acsnano.6b02819 · Cited by 219
Singlet Oxygen, Photodynamic Therapy, and Mechanisms of Cancer Cell Death
Maharjan, P. S., & Bhattarai, H. K. (2022) · Journal of Oncology · doi:10.1155/2022/7211485 · Cited by 222
Phototheranostics: Active Targeting of Orthotopic Glioma Using Biomimetic Proteolipid Nanoparticles
Jia, Y., Wang, X., Hu, D., Wang, P., Liu, Q., Zhang, X., Jiang, J., Liu, X., Sheng, Z., Liu, B., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b06556 · Cited by 211
Aptamer-guided nanomedicines for anticancer drug delivery
Alshaer, W., Hillaireau, H., & Fattal, E. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.09.011 · Cited by 187
Ramanathan, R. K., Korn, R. L., Raghunand, N., Sachdev, J. C., Newbold, R. G., Jameson, G., Fetterly, G. J., Prey, J., Klinz, S. G., Kim, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1990 · Cited by 183
Xiao, W., Wang, Y., Zhang, H., Liu, Y., Xie, R., He, X., Zhou, Y., Liang, L., & Gao, H. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120888 · Cited by 174
Leveraging Physiology for Precision Drug Delivery
Sun, W., Hu, Q., Ji, W., Wright, G., & Gu, Z. (2017) · Physiological Reviews · doi:10.1152/physrev.00015.2016 · Cited by 169
Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy
Mohanty, A., Uthaman, S., & Park, I.-K. (2020) · Molecules · doi:10.3390/molecules25194377 · Cited by 160
The in vivo fate of polymeric micelles
Cai, Y., Qi, J., Lu, Y., He, H., & Wu, W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114463 · Cited by 154
Advancing engineering design strategies for targeted cancer nanomedicine
Gomerdinger, V. F., Nabar, N., & Hammond, P. T. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-025-00847-2 · Cited by 146
Ultrasensitive tumour-penetrating nanosensors of protease activity
Kwon, E. J., Dudani, J. S., & Bhatia, S. N. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0054 · Cited by 131
Sato, M., Sasaki, N., Ato, M., Hirakawa, S., Sato, K., & Sato, K. (2015) · PLOS ONE · doi:10.1371/journal.pone.0137301 · Cited by 124
Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy
Pérez-Medina, C., Abdel-Atti, D., Tang, J., Zhao, Y., Fayad, Z. A., Lewis, J. S., Mulder, W. J. M., & Reiner, T. (2016) · Nature Communications · doi:10.1038/ncomms11838 · Cited by 128
Nexus between in silico and in vivo models to enhance clinical translation of nanomedicine
Moradi Kashkooli, F., Soltani, M., Souri, M., Meaney, C., & Kohandel, M. (2021) · Nano Today · doi:10.1016/j.nantod.2020.101057 · Cited by 120
Gold nanoparticles enhance 5-fluorouracil anticancer efficacy against colorectal cancer cells
Safwat, M. A., Soliman, G. M., Sayed, D., & Attia, M. A. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.09.076 · Cited by 109
Chemotherapeutic drug delivery by tumoral extracellular matrix targeting
Raavé, R., van Kuppevelt, T. H., & Daamen, W. F. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.029 · Cited by 106
Clinically approved liposomal nanomedicines: lessons learned from the biomolecular corona
Caracciolo, G. (2018) · Nanoscale · doi:10.1039/c7nr07450f · Cited by 106
Tiwari, P., Yadav, K., Shukla, R. P., Gautam, S., Marwaha, D., Sharma, M., & Mishra, P. R. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.016 · Cited by 88
Luiz, M. T., Abriata, J. P., Raspantini, G. L., Tofani, L. B., Fumagalli, F., de Melo, S. M. G., Emery, F. D. S., Swiech, K., Marcato, P. D., Lee, R., et al. (2019) · Materials Science and Engineering: C · doi:10.1016/j.msec.2019.110038 · Cited by 63
Gao, W., Ye, G., Duan, X., Yang, X., & Yang, V. C. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s115215 · Cited by 57
Banerjee, S. R., Foss, C. A., Horhota, A., Pullambhatla, M., McDonnell, K., Zale, S., & Pomper, M. G. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.6b01485 · Cited by 54
Novel EPR-enhanced strategies for targeted drug delivery in pancreatic cancer: An update
Mohammadzadeh, V., Rahiman, N., Hosseinikhah, S. M., Barani, M., Rahdar, A., Jaafari, M. R., Sargazi, S., Zirak, M. R., Pandey, S., Bhattacharjee, R., et al. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103459 · Cited by 50
Synergistic vesicle-vector systems for targeted delivery
Marquez, C. A., Oh, C.-I., Ahn, G., Shin, W.-R., Kim, Y.-H., & Ahn, J.-Y. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02275-6 · Cited by 37
Debele, T. A., Mekuria, S. L., & Tsai, H.-C. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.01.103 · Cited by 36
Gupta, P. K., Tripathi, S. K., Pappuru, S., Chabattula, S. C., Govarthanan, K., Gupta, S., Biswal, B. K., Chakraborty, D., & Verma, R. S. (2020) · Materials Science and Engineering: C · doi:10.1016/j.msec.2019.110285 · Cited by 29
Strittmatter, N., Moss, J. I., Race, A. M., Sutton, D., Canales, J. R., Ling, S., Wong, E., Wilson, J., Smith, A., Howes, C., et al. (2022) · Theranostics · doi:10.7150/thno.68000 · Cited by 25
“Prolonged plasma circulation time has been shown to be critical for good tumor accumulation of nanomedicines [45, 46].”
BackgroundSmith, D. J., Leal, L. G., Mitragotri, S., & Shell, M. S. (2018) · Journal of Physics D: Applied Physics · doi:10.1088/1361-6463/aacac9 · Cited by 23
“Especially with the possibility of disruptive membrane pore formation [29], it seems likely for nanoscale NPs that, in addition to the partition coefficient, properties like NP size, surface chemistry, shape, and softness [11, 19, 31] and their impact on the local details of the membrane must be taken into account.”
BackgroundAsadi, N., Gharbavi, M., Rezaeejam, H., Farajollahi, A., & Johari, B. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124285 · Cited by 23
Insights into Nanomedicine for Head and Neck Cancer Diagnosis and Treatment
Viegas, C., Pereira, D. S. M., & Fonte, P. (2022) · Materials · doi:10.3390/ma15062086 · Cited by 21
“In this sense, to personalize the therapeutic approach to be taken with each user, it is essential to understand the biological mechanisms related to the distribution and retention of nanocarriers in tumors [48,71].”
BackgroundA simple, fast, and orientation-controllable technology for preparing antibody-modified liposomes
Hirata, Y., Tashima, R., Mitsuhashi, N., Yoneda, S., Ozono, M., Fukuta, T., Majima, E., & Kogure, K. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120966 · Cited by 16
Chen, Q., Long, M., Qiu, L., Zhu, M., Li, Z., Qiao, M., Hu, H., Zhao, X., & Chen, D. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s111950 · Cited by 16
Yin, X., Li, Z., Zhang, Y., Zeng, X., Wang, Q., & Liang, Z. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1174014 · Cited by 15
Metadata
- Authors
- Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 66
- Pages
- 2-25
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2153771870
- Cited by
- 2,824
- References
- 302
- FWCI
- 10.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.